The Impact of CYP1A2 and CYP2E1 Genes Polymorphism on Theophylline Response

Overview

Journal J Clin Diagn Res

Specialty General Medicine

Date 2017 Jan 5

PMID 28050398

Citations 3

Authors

Em Sutrisna

Affiliations

Soon will be listed here.

Abstract

Theophylline is a medicine with narrow therapeutic index. This implies that a small change in dosage would cause side effects. Theophylline is metabolized by CYP1A2 and CYP2E1. The aim of this review is to know the impact of CYP1A2 and CYP2E1 genes polymorphism on theophylline response. The review was done by searching literature in Pubmed and Science Direct databases with keywords 'polymorphism', 'pharmacogenetic', 'CYP1A2', 'CYP2E1' and 'theophylline'. There were 5 research articles from Pubmed and 65 articles (21 research articles, 23 review articles and 21 book chapters) from Science Direct. The exclusion criteria were - articles discussing about polymorphism but not CYP1A2 or CYP2E1, the ones with a mention of theophylline but not about its metabolism, articles on CYP1A2 and/or 2E1 polymorphism but not on the effect on theophylline. Thus, 33 articles were reviewed due to their suitability. The review discusses the influence of polymorphism of CYP1A2 and CYP2E1 genes on theophylline response.

Citing Articles

Theophylline use-a conundrum in modern medicine: a case report.

Kommineni S, Gullapalli D, Rahmlow T, Ganti S, Depa J AME Case Rep. 2025; 9():1.

PMID: 39866267 PMC: 11760928. DOI: 10.21037/acr-24-111.

Contribution of CYP19A1, CYP1A1, and CYP1A2 polymorphisms in coronary heart disease risk among the Chinese Han population.

Ye W, Tang Q, Wang L, Fang C, Xie L, He Q Funct Integr Genomics. 2022; 22(4):515-524.

PMID: 35380334 DOI: 10.1007/s10142-022-00850-y.

Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization.

Doohan P, Oldfield L, Arnold J, Anderson L AAPS J. 2021; 23(4):91.

PMID: 34181150 DOI: 10.1208/s12248-021-00616-7.

The effect of gene polymorphism on the metabolism of theophylline.

Xiong S, Li L Exp Ther Med. 2018; 15(1):109-114.

PMID: 29387184 PMC: 5769306. DOI: 10.3892/etm.2017.5396.

References

Yoon Y, Park H, Park K, Kim J, Chang Y, Song J . Associations between CYP2E1 promoter polymorphisms and plasma 1,3-dimethyluric acid/theophylline ratios. Eur J Clin Pharmacol. 2006; 62(8):627-31. DOI: 10.1007/s00228-006-0165-4. View

Zhou S, Wang B, Yang L, Liu J . Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev. 2009; 42(2):268-354. DOI: 10.3109/03602530903286476. View

Mitenko P, OGILVIE R . Rational intravenous doses of theophylline. N Engl J Med. 1973; 289(12):600-3. DOI: 10.1056/NEJM197309202891202. View

Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T . Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem. 1999; 125(4):803-8. DOI: 10.1093/oxfordjournals.jbchem.a022352. View

Robson R, Miners J, Matthews A, Stupans I, Meller D, McManus M . Characterisation of theophylline metabolism by human liver microsomes. Inhibition and immunochemical studies. Biochem Pharmacol. 1988; 37(9):1651-9. DOI: 10.1016/0006-2952(88)90423-6. View

Zanger U, Schwab M . Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013; 138(1):103-41. DOI: 10.1016/j.pharmthera.2012.12.007. View

Aklillu E, Carrillo J, Makonnen E, Hellman K, Pitarque M, Bertilsson L . Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol. 2003; 64(3):659-69. DOI: 10.1124/mol.64.3.659. View

Zhou S, Yang L, Zhou Z, Liu Y, Chan E . Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J. 2009; 11(3):481-94. PMC: 2758120. DOI: 10.1208/s12248-009-9127-y. View

Rossini A, Lima S, Rapozo D, Faria M, Albano R, Pinto L . CYP2A6 and CYP2E1 polymorphisms in a Brazilian population living in Rio de Janeiro. Braz J Med Biol Res. 2006; 39(2):195-201. DOI: 10.1590/s0100-879x2006000200005. View

10.

Hammons G, Guengerich F, Weis C, Beland F, Kadlubar F . Metabolic oxidation of carcinogenic arylamines by rat, dog, and human hepatic microsomes and by purified flavin-containing and cytochrome P-450 monooxygenases. Cancer Res. 1985; 45(8):3578-85. View

11.

Rasmussen B, Maenpaa J, Pelkonen O, Loft S, Poulsen H, Lykkesfeldt J . Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol. 1995; 39(2):151-9. PMC: 1364952. DOI: 10.1111/j.1365-2125.1995.tb04422.x. View

12.

Yim E, Kang H, Jung J, Sohn S, Cho S . CYP1A2 polymorphism and theophylline clearance in Korean non-smoking asthmatics. Asia Pac Allergy. 2013; 3(4):231-40. PMC: 3826610. DOI: 10.5415/apallergy.2013.3.4.231. View

13.

Obase Y, Shimoda T, Kawano T, Saeki S, Tomari S, Mitsuta-Izaki K . Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma. Clin Pharmacol Ther. 2003; 73(5):468-74. DOI: 10.1016/s0009-9236(03)00013-4. View

14.

Allorge D, Chevalier D, Lo-Guidice J, Cauffiez C, Suard F, Baumann P . Identification of a novel splice-site mutation in the CYP1A2 gene. Br J Clin Pharmacol. 2003; 56(3):341-4. PMC: 1884342. DOI: 10.1046/j.1365-2125.2003.01858.x. View

15.

Chen X, Wang L, Zhi L, Zhou G, Wang H, Zhang X . The G-113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population. Clin Pharmacol Ther. 2005; 78(3):249-59. DOI: 10.1016/j.clpt.2005.05.012. View

16.

Ingelman-Sundberg M . The human genome project and novel aspects of cytochrome P450 research. Toxicol Appl Pharmacol. 2005; 207(2 Suppl):52-6. DOI: 10.1016/j.taap.2005.01.030. View

17.

Sachse C, Brockmoller J, Bauer S, Roots I . Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol. 1999; 47(4):445-9. PMC: 2014233. DOI: 10.1046/j.1365-2125.1999.00898.x. View

18.

Flockhart D, Oesterheld J . Cytochrome P450-mediated drug interactions. Child Adolesc Psychiatr Clin N Am. 2000; 9(1):43-76. View

19.

Grygiel J, Wing L, Farkas J, Birkett D . Effects of allopurinol on theophylline metabolism and clearance. Clin Pharmacol Ther. 1979; 26(5):660-7. DOI: 10.1002/cpt1979265660. View

20.

HALEY T . Metabolism and pharmacokinetics of theophylline in human neonates, children, and adults. Drug Metab Rev. 1983; 14(2):295-335. DOI: 10.3109/03602538308991392. View